Abstract
A new hypoxic cell radiosensitizer, Ro 03-8799, has been administered i.v. to 2 normal and 6 patient volunteers. Generally in non-necrotic tumours the concentrations obtained were 3 times greater than in plasma sampled at the same time. These observations added to the reports concerning toxicology in monkeys and rats and radiosensitizing efficiency in the laboratory, suggest that Ro 03-8799 may prove to be much more effective sensitizer than misonidazole in man.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Saunders, M., Dische, S., Fermont, D. et al. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study. Br J Cancer 46, 706–710 (1982). https://doi.org/10.1038/bjc.1982.262
Issue Date:
DOI: https://doi.org/10.1038/bjc.1982.262
This article is cited by
-
Morphological changes in rat hepatocytes in primary culture induced by Misonidazole, desmethylmisonidazole and Ro 03-8799
Virchows Archiv B Cell Pathology Including Molecular Pathology (1984)
-
The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans
European Journal of Clinical Pharmacology (1984)
